CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team

Rhea-AI Summary

CNS Pharmaceuticals (NASDAQ:CNSP) appointed Lynne Kelley, MD, FACS as Chief Medical Officer effective March 2, 2026, completing its executive leadership team. Dr. Kelley brings more than two decades of clinical development, translational medicine and global regulatory strategy across oncology, rare diseases, CNS and medical devices.

She has led Phase 1–3 programs, supported INDs, NDAs, BLAs, PMAs and breakthrough/orphan designations, and has prior CMO roles at multiple biotechs and leadership experience at Boston Scientific and Becton Dickinson.

Positive

• CMO appointment of Lynne Kelley effective March 2, 2026
• Over 20 years of clinical development and regulatory experience
• Global regulatory track record across United States, Europe, China and Japan
• Led Phase 1–3 programs and contributed to INDs, NDAs, BLAs and breakthrough/orphan designations

Negative

• None.

Key Figures

Drug development experience: two decades Clinical program stages: Phase 1-3

2 metrics

Drug development experience two decades Dr. Kelley’s experience in oncology, rare diseases and CNS

Clinical program stages Phase 1-3 Programs Dr. Kelley has successfully led

Market Reality Check

Price: $3.11 Vol: Volume 11,883 is below th...

low vol

$3.11 Last Close

Volume Volume 11,883 is below the 20-day average of 21,584, indicating muted trading interest pre-announcement. low

Technical Shares at $3.11 are trading below the 200-day MA of $7.93 and far under the $55.20 52-week high.

Peers on Argus

CNSP was up 1.3% while peers showed mixed moves: JAGX +3.48%, XBIO +7.2%, TOVX +...

1 Up 1 Down

CNSP was up 1.3% while peers showed mixed moves: JAGX +3.48%, XBIO +7.2%, TOVX +2.56%, QNRX -1.41%. Momentum scanner flagged TOVX -7.65% and BDRX +3.7%, reinforcing a stock-specific rather than sector-driven backdrop.

Historical Context

5 past events · Latest: Feb 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	Executive appointments	Positive	-5.8%	New CFO, CTO and CBO hired to drive strategic transformation.
Jan 27	Strategic update	Positive	+0.8%	CEO letter outlining strategic review and focus on lead asset TPI 287.
Dec 17	CEO transition	Positive	-6.4%	Appointment of new CEO with extensive biopharma experience and growth record.
Nov 17	Earnings and update	Positive	-2.9%	Q3 loss reduction, cash runway into 2H 2026, and encouraging TPI 287 data.
Nov 10	Scientific posters	Positive	-1.2%	Three abstracts accepted for presentation on berubicin and TPI 287 programs.

Pattern Detected

Recent history shows CNSP often trading down on generally positive corporate updates, indicating a pattern of negative price reactions to leadership and pipeline news.

Recent Company History

Over the past few months, CNS Pharmaceuticals has focused on leadership transition and strategic repositioning. A new CEO, Rami Levin, was announced on Dec 17, 2025, followed by a shareholder letter on Jan 27, 2026 outlining strategic evaluation and prioritization of TPI 287. On Feb 17, 2026, multiple senior executives were appointed to drive a strategic transformation. Earlier, Q3 2025 results on Nov 17, 2025 highlighted reduced net loss and promising TPI 287 data. Despite broadly constructive news, several of these events saw negative next‑day price reactions.

Market Pulse Summary

This announcement adds an experienced Chief Medical Officer with two decades of drug development and...

Analysis

This announcement adds an experienced Chief Medical Officer with two decades of drug development and regulatory work across oncology, rare diseases and CNS, complementing the new executive team and ongoing strategic transformation. In context of earlier CEO and leadership changes and a focus on TPI 287, this hire reinforces execution capabilities. Key factors to watch include future clinical trial designs, regulatory interactions, and how swiftly the team translates this expertise into measurable development milestones.

Key Terms

pmas, orphan drug designations, fda advisory committees

3 terms

pmas regulatory

"She has led clinical development programs resulting in INDs, NDAs, BLAs, PMAs, and breakthrough..."

Premarket approvals (PMAs) are the U.S. Food and Drug Administration’s formal approvals for high‑risk medical devices, granted after a full review of clinical and technical evidence showing the device is safe and effective. For investors, a granted PMA is like a government green light allowing a product to be sold widely, often unlocking significant revenue potential while also reducing regulatory uncertainty and legal risk compared with unapproved devices.

orphan drug designations regulatory

"INDs, NDAs, BLAs, PMAs, and breakthrough and orphan drug designations, and has global regulatory..."

A regulatory status granted to medicines that treat rare diseases, giving developers special incentives and protections — for example, reduced fees, tax benefits, and a period of exclusive marketing once approved. Think of it as a government “boost” that lowers development costs and shields a product from direct competition for a time; investors watch for it because it can raise a drug’s commercial value and reduce the financial risk of bringing a treatment for a small patient group to market.

fda advisory committees regulatory

"designing clinical trials as well as interactions with FDA advisory committees that resulted..."

FDA advisory committees are independent panels of outside experts—such as doctors, scientists and patient advocates—that review evidence about a drug, device or medical test and give the U.S. Food and Drug Administration a nonbinding recommendation on whether it should be approved or given a new use. Think of them as a trusted jury whose opinion can strongly influence the regulator’s decision; their advice often moves investor expectations and share prices because it affects a product’s chance of reaching the market.

AI-generated analysis. Not financial advice.

Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNS

Newly formed executive team is committed to execution and company evolution focused on patient and stakeholder value

HOUSTON, TX / ACCESS Newswire / March 2, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer.

Dr. Kelley brings more than two decades of global leadership experience across clinical development, translational medicine and regulatory strategy in oncology, rare diseases, CNS and medical devices. She has successfully led Phase 1-3 clinical programs and supported regulatory approvals across the United States, Europe, China, and Japan, and is widely recognized for building high-performing medical organizations and delivering successful regulatory and commercial outcomes.

"The depth, breadth and experience that Dr. Kelley brings to the Company will be instrumental as we prioritize and strategically build our pipeline. She is an exceptional medical leader with deep expertise in oncology, CNS and rare disease drug development and will play a key role in driving the Company forward, creating meaningful advancements for patients and significant value for our shareholders," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals.

Prior to joining CNS Pharmaceuticals, Dr. Kelley served as Chief Medical Officer at multiple public and private biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4 Pharmaceuticals and Senseonics. She has led clinical development programs resulting in INDs, NDAs, BLAs, PMAs, and breakthrough and orphan drug designations, and has global regulatory experience designing clinical trials as well as interactions with FDA advisory committees that resulted in unanimous approval votes. Dr. Kelley has also played key roles in corporate strategy, fundraising and M&A, including contributing to multi-billion-dollar oncology transactions.

Earlier in her career, Dr. Kelley held senior leadership roles at Boston Scientific and Becton Dickinson, where she oversaw global medical affairs and regulatory strategy across devices, drugs and combination products. She began her career in academic medicine as an Assistant Professor of Surgery and Interventional Radiology at Yale University.

"It is such a rare opportunity to be part of building the next chapter of a company," added Dr. Kelley. "I am very excited to join CNS Pharmaceuticals at this important stage in the Company's growth and honored to work with this hand selected executive leadership team who all share a vision and have the ability to meaningfully deliver results for patients and stakeholders alike."

Dr. Kelley holds an MD from Dartmouth Medical School and a BA in Biology from Boston University. She is licensed in Massachusetts, was board certified in General Surgery and Vascular Surgery and is a Fellow of the American College of Surgeons.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma and breast cancer metastatic to the brain. To date TPI 287 appears to have both an excellent safety profile and high tolerability among patients.

For more information, please visit www.CNSPharma.com, and connect with the Company on X and LinkedIn.

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's pipeline prioritization and strategic development, the anticipated contributions of the new management team to the Company's growth, and expectations regarding clinical development and regulatory strategy. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

CONTACTS:

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com

SOURCE: CNS Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

FAQ

Who is Lynne Kelley and what role did she accept at CNS Pharmaceuticals (CNSP)?

Dr. Lynne Kelley accepted the role of Chief Medical Officer at CNS Pharmaceuticals on March 2, 2026. According to the company, she brings more than two decades of clinical development, translational medicine and regulatory strategy experience across oncology, CNS, rare diseases and devices.

What specific experience does Dr. Kelley bring to CNS Pharmaceuticals (CNSP)?

Dr. Kelley brings over 20 years leading Phase 1–3 clinical programs and global regulatory interactions. According to the company, her background includes INDs, NDAs, BLAs, PMAs and breakthrough and orphan drug designations across major markets.

How might the CMO appointment affect CNS Pharmaceuticals' (CNSP) clinical development plans?

The appointment strengthens clinical leadership and regulatory strategy at CNS Pharmaceuticals. According to the company, Dr. Kelley will prioritize pipeline development, leveraging prior experience with global trial design and FDA advisory committee interactions to advance programs.

What prior companies and roles has Dr. Kelley held before joining CNS Pharmaceuticals (CNSP)?

Dr. Kelley previously served as Chief Medical Officer at multiple biotech and device companies and held senior leadership at Boston Scientific and Becton Dickinson. According to the company, she has led medical affairs, regulatory strategy and clinical programs globally.

When did CNS Pharmaceuticals announce the completion of its executive leadership team with this hire?

CNS Pharmaceuticals announced the CMO appointment on March 2, 2026, noting the executive leadership team is now complete. According to the company, the team is focused on executing the pipeline and creating value for patients and shareholders.

Does Dr. Kelley have experience with regulatory approvals and advisory committees relevant to CNS Pharmaceuticals (CNSP)?

Yes. Dr. Kelley has supported regulatory approvals and participated in FDA advisory committee processes that led to unanimous approval votes. According to the company, she has experience designing global trials and securing regulatory designations.